Search

Search Constraints

You searched for: Author/Creator Mirza, Mansoor R

Search Results

1. 2022-RA-1144-ESGO Management of immune-related adverse events in patients with solid tumours treated with dostarlimab in the GARNET study. (20th October 2022)

2. 2022-RA-1194-ESGO Efficacy of dostarlimab in endometrial cancer by molecular subtype: a post hoc analysis of the GARNET study. (20th October 2022)

3. 2022-RA-1267-ESGO A randomised clinical Trial Investigating olaparib, durvalumab and an anticancer vaccine, UV1 as maintenance therapy in patients with recurrent ovarian cancer. ENGOT-OV56-NSGO-CTU-DOVACC. (20th October 2022)

6. Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer. Issue 7 (15th August 2019)

7. Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer. Issue 7 (September 2019)

8. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. Issue 8 (August 2018)

9. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Issue 8 (August 2015)

10. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Issue 8 (August 2015)